Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease
06 nov. 2020 08h35 HE
|
Equillium
100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date Complete response observed in seven of eight responding patients EQUATE Phase 1b topline data...
Inspirata Partners with Carebox to Deliver Powerful, Automated, Real-Time Clinical Trial Matching to Oncologists
13 oct. 2020 09h00 HE
|
Inspirata, Inc.
Tampa, Florida / Raleigh, North Carolina, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Cancer and clinical informatics solution provider Inspirata announced today a technology collaboration with Carebox. The...
CHF Solutions Announces Data Demonstrating Benefit of Aquadex Therapy for Treatment of Heart Failure and COVID-19
07 oct. 2020 08h00 HE
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Oct. 07, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today...
Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results
20 août 2020 06h30 HE
|
Entera Bio Ltd.
‒ 6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner –‒ Company Expects to Complete Patient Enrollment in...
CHF Solutions Announces Registry for Fluid Overload Conditions in Pediatric Patients
16 juil. 2020 08h00 HE
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., July 16, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, today...
Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health
13 juil. 2020 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge, MA, US, July 13, 2020...
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
13 juil. 2020 03h30 HE
|
Equillium
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon has received emergency use approval from Drugs Controller General of...
Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results
21 mai 2020 06h30 HE
|
Entera Bio Ltd.
‒ Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 ‒‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through Six...
CHF Solutions Announces COVID-19 Patients Treated with Aquadex Therapy for Fluid Management When Access to Dialysis Machines is Limited or Not Available
14 avr. 2020 08h00 HE
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., April 14, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced that...
CHF Solutions Announces Presentation of Clinical Data with Aquadex FlexFlow® Highlighting Efficacy and Simplicity of Use In Treating Critical Care Patients
08 janv. 2020 08h00 HE
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Jan. 08, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced results from an investigator-initiated retrospective analysis of utilization of the Aquadex...